Tucson startup looks to human trials for drug to treat lung inflammation
Aqualung Therapeutics, a Tucson-based drug startup headed by a University of Arizona pulmonologist, has won a major investment
Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models
Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models ByACCESSWIRE Published February 1,
Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer
Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer TUCSON, AZ / ACCESSWIRE / January
Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor
Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor Tuesday,
CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase in San Francisco
CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech
Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition on October 6-7th
Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition on October 6-7th
Dr. Garcia Grand Rounds at Houston Methodist: A Systems Biology Journey to DAMPen Acute Lung Inflammation
Dr. Garcia Grand Rounds at Houston Methodist: A Systems Biology Journey to DAMPen Acute Lung Inflammation
Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting
Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting Phase 0
CEO of Aqualung Therapeutics Corp., Joe G.N. Garcia MD, Named Invited Speaker at the First Annual Acute Respiratory Distress Syndrome Drug Development Summit
CEO Of Aqualung Therapeutics Corp., Joe G.N. Garcia MD, Named Invited Speaker at the First Annual Acute Respiratory Distress Syndrome Drug
Studies: eNAMPT, an inflammation-regulatory protein is now tightly linked to COVID-19 deaths
Studies: eNAMPT, an inflammation-regulatory protein is now tightly linked to COVID-19 deaths LINK TO FULL ARTICLE 2.13.21 Studies: eNAMPT, an inflammation-regulatory protein is now tightly
eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients
eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients LINK TO PRESS
Dr. Joe GN Garcia speaks on the impacts of COVID-19 in the year 2020 in PharmaVOICE Magazine Nov/Dec Issue
Dr. Joe GN Garcia speaks on the impacts of COVID-19 in the year 2020 in PharmaVOICE Magazine
Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer; Prostate Cancer KOL New Addition to Scientific Advisory Board
READ PRESS RELEASE 12.2.20 Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer; Prostate Cancer KOL New Addition to
Aqualung Therapeutics Corp. Awarded $300 Thousand From National Institute of Health (NIH) to Develop a Novel Therapeutic for Pregnant Women at Risk for Preterm Births
Aqualung Therapeutics Corp. Awarded $300 Thousand From National Institute of Health (NIH) to Develop a Novel Therapeutic for Pregnant Women at